Pulmonary Vascular Complications of Liver Disease-2

Overview

About this study

The purpose of this study is to determine if certain genes, hormones, or other factors predict the risk of developing lung vessel disease in patients with liver disease and whether they determine outcome.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria

  • Chronic portal hypertension from intrinsic liver disease or portal vein disease, documented by clinical history or liver biopsy
  • Referral for evaluation for liver transplantation (LT) or portopulmonary hypertension (or a known diagnosis of portopulmonary hypertension)
  • Informed consent
  • Age ≥ 21 years

Exclusion Criteria

  • Active infection
  • Active or recent (< 2 weeks) gastrointestinal bleeding
  • Lung transplant or LT recipients
  • Pregnant women

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Krowka, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20315015

Mayo Clinic Footer